| March 2023 | Our CSO, Graham Pockley, PhD is presenting at the 8th Annual Innate Killer Summit in San Diego, USA |
| October 2021 | Alphageneron Announces Successful Completion of FDA Pre-IND Meeting of Proposed Phase II Clinical Trial for NK Cell Therapy with Advanced (stage III & Stage IV) NSCLC Patients |
| June 2021 | Alphageneron to participate in Roth Capital Partners Virtual Healthcare Private Company Forum |
| February 2021 | Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide |
